Oncogenic mutations in B-Raf: Some losses yield gains

被引：14

作者：

Hubbard, SR

机构：

[1] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA

[2] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA

来源：

CELL | 2004年 / 116卷 / 06期

关键词：

D O I：

10.1016/S0092-8674(04)00256-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A study by Wan et al. in this issue of Cell demonstrates that the majority of oncogenic mutations in the B-Raf protein kinase result in increased catalytic activity, through disruption of the autoinhibited state of the kinase domain. Surprisingly, several mutations lead to impaired B-Raf kinase activity, yet these mutants are nevertheless capable of stimulating downstream signaling through transactivation of C-Raf.

引用

页码：764 / 766

页数：3

共 9 条

[1]

BOS JL, 1989, CANCER RES, V49, P4682

[2] Positive and negative regulation of Raf kinase activity and function by phosphorylation [J].

Chong, H ;

Lee, J ;

Guan, KL .

EMBO JOURNAL, 2001, 20 (14) :3716-3727

[3] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[4] Active and inactive protein kinases: Structural basis for regulation [J].

Johnson, LN ;

Noble, MEM ;

Owen, DJ .

CELL, 1996, 85 (02) :149-158

[5] Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions [J].

Kolch, W .

BIOCHEMICAL JOURNAL, 2000, 351 :289-305

[6] Timeline - RAS oncogenes: the first 30 years [J].

Malumbres, M ;

Barbacid, M .

NATURE REVIEWS CANCER, 2003, 3 (06) :459-465

[7] Bypassing a kinase activity with an ATP-competitive drug [J].

Papa, FR ;

Zhang, C ;

Shokat, K ;

Walter, P .

SCIENCE, 2003, 302 (5650) :1533-1537

[8] Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase [J].

Schindler, T ;

Bornmann, W ;

Pellicena, P ;

Miller, WT ;

Clarkson, B ;

Kuriyan, J .

SCIENCE, 2000, 289 (5486) :1938-1942

[9] Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF [J].

Wan, PTC ;

Garnett, MJ ;

Roe, SM ;

Lee, S ;

Niculescu-Duvaz, D ;

Good, VM ;

Jones, CM ;

Marshall, CJ ;

Springer, CJ ;

Barford, D ;

Marais, R .

CELL, 2004, 116 (06) :855-867

← 1 →